← Tectonic Therapeutic, Inc. (TECX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Tectonic Therapeutic, Inc. (TECX)
Biological Products, (No Diagnostic Substances) · market cap $486M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
1
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Tectonic Therapeutic, Inc. (TECX) is a small-cap biotech (~$605M market cap, 51 employees) with a single clinical-stage asset, TX000045 at Dose A, currently in Phase 2 for Pulmonary Hypertension. The company holds $236.9M in cash (~38.6 months of runway) and trades at roughly $32, well below the analyst consensus target of ~$78. The key binary is an estimated Phase 2 data readout around November 2026.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2026-11-24 (est.)Phase 2 · TX000045- Dose Aimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| TX000045- Dose A | Phase 2 | Pulmonary Hypertension |
Price & technical context
3-month
-40.2%
6-month
-26.3%
12-month
+44.5%
52-wk range
$14.91–$37.93
vs 50-day MA
-25.4%
vs 200-day MA
-18.9%
Realized vol
73.7%
Max drawdown
-73.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TECX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.